NIT1

Across TCGA pan-cancer cohorts, NIT1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NIT1 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher NIT1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated NIT1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, COAD, and CCRCC are the cancer types where NIT1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.580	0.318	.001	38	view →
COAD	DFS	Median	II,III,IV	0.879	1.000	.019	18	view →
CCRCC	DFS	Quartile	All	0.673	0.953	.012	8	view →
OV	DFS	Median	All	0.874	1.000	.047	4	view →
LSCC	DFS	Quartile	II,III,IV	0.888	0.200	.024	4	view →
LUAD	DFS	Median	II,III,IV	0.788	0.918	.022	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

NIT1–PDAC (OS)

Open the PDAC breakdown →